Medicare gets AI-powered push to take meds, save money on generics
H.R. 1142 — To amend the Public Health Service Act to direct the Secretary of Health and Human Services to establish drug adherence guidelines, and for other purposes. · Filed by David Schweikert (R-AZ) · Introduced Feb 7, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Secretary of Health and Human Services to create guidelines aimed at getting Medicare patients to take their prescribed drugs 90% of the time. The guidelines must use artificial intelligence and machine learning, and should encourage the use of cheaper generic and biosimilar drugs where possible.
Why we flagged it
The bill is a straightforward directive to establish clinical guidelines aimed at improving medication adherence and reducing drug costs for Medicare beneficiaries. It is a public-health intervention, not a regulatory carve-out or appropriation.
What the text implies
- AI/ML-driven adherence monitoring may create detailed patient behavioral data; privacy safeguards are not addressed in the bill itself and would depend on HHS implementation.
- Promotion of generics and biosimilars may reduce revenue for brand-name manufacturers, creating potential industry resistance to aggressive guideline implementation.
The full analysis lists 3 implications of this text.
Who stands to gain
generic drug manufacturers; biosimilar manufacturers; Medicare (reduced costs from lower drug prices and fewer complications)